Sector Gamma As
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 13, 2024), Sector Gamma As reported 29 stock positions worth $329.6 million. Its top holding was Bristol-Myers Squibb (BMY) at 9.5% of the portfolio, followed by Medtronic (MDT, 9.1%) and Gilead Sciences (GILD, 7.4%). Compared with Q2 2024, it opened 4 new positions, sold out of 3, added to 15 and reduced 8. The biggest buy was a new position in Becton Dickinson and (BDX) and the biggest sale Gilead Sciences (GILD, shares −31%).
- Most Recent 13F
- Q2 2026
- Location
- OSLO, Q8
- CIK
- 0001475373
- Portfolio Value
- $329.6M (Q3 2024)
- SEC Filing
- 0000945621-24-000926 ↗ filed Nov 13, 2024
Holdings Value
Holdings 29 stocks · $329.6M
| BMY Bristol-Myers Squibb Co. | 9.45% | 602,000 | $31.1M | Add +12.5% |
| MDT Medtronic PLC | 9.15% | 334,890 | $30.2M | Add +26.4% |
| GILD Gilead Sciences Inc. | 7.36% | 289,163 | $24.2M | Reduce -31.2% |
| PFE Pfizer Inc. | 7.20% | 820,000 | $23.7M | Reduce -8.4% |
| CVS CVS Health Corp. | 5.76% | 302,000 | $19.0M | Add +37.3% |
| BDX Becton Dickinson and Co. | 5.65% | 77,280 | $18.6M | New |
| INCY Incyte Corp. | 5.19% | 259,000 | $17.1M | Add +27.4% |
| BAX Baxter International Inc. | 4.44% | 385,000 | $14.6M | Add +48.1% |
| ELV Elevance Health Inc. | 4.15% | 26,279 | $13.7M | Add +8.2% |
| BMRN Biomarin Pharmaceutical Inc. | 4.06% | 190,348 | $13.4M | Add +200.5% |
| CAH Cardinal Health Inc. | 3.93% | 117,098 | $12.9M | Add +9.3% |
| ZBH Zimmer Biomet Holdings Inc. | 3.47% | 106,000 | $11.4M | Add +24.7% |
| BRKR Bruker Corp. | 3.33% | 158,970 | $11.0M | Add +37.7% |
| QGEN Qiagen NV | 3.08% | 223,124 | $10.2M | Add +167.3% |
| GEHC GE Healthcare Technology | 3.04% | 106,700 | $10.0M | Add +2.6% |
| IONS Ionis Pharmaceuticals Inc. | 2.56% | 210,842 | $8.4M | Add +24.0% |
| CNC Centene Corp. | 2.17% | 95,000 | $7.2M | Add +111.1% |
| EW Edwards Lifesciences Corp. | 2.13% | 106,153 | $7.0M | Add +53.5% |
| BIIB Biogen Inc. | 2.07% | 35,166 | $6.8M | Reduce -20.1% |
| BIO Bio-Rad Laboratories-A | 1.71% | 16,829 | $5.6M | No change |
| AMGN Amgen Inc. | 1.56% | 16,000 | $5.2M | Reduce -46.7% |
| BNTX Biontech SE-ADR | 1.44% | 40,000 | $4.8M | New |
| THC Tenet Healthcare Corp. | 1.33% | 26,361 | $4.4M | Reduce -50.1% |
| UHS Universal Health Services-B | 1.22% | 17,627 | $4.0M | Reduce -49.6% |
| HUM Humana Inc. | 1.15% | 12,000 | $3.8M | New |
| LNTH Lantheus Holdings Inc. | 1.06% | 31,712 | $3.5M | No change |
| AGIO Agios Pharmaceuticals Inc. | 0.92% | 67,908 | $3.0M | Reduce -44.3% |
| ALKS Alkermes PLC | 0.85% | 100,000 | $2.8M | Reduce -48.5% |
| LEGN Legend Biotech Corp.-ADR | 0.57% | 38,762 | $1.9M | New |
Portfolio Sells Q2 2024 → Q3 2024
| GILD Gilead Sciences Inc. | Reduce -31.2% | 7.36% | −3.41 |
| ABT Abbott Laboratories | Sold out | 0.00% | −2.72 |
| PFE Pfizer Inc. | Reduce -8.4% | 7.20% | −2.15 |
| AMGN Amgen Inc. | Reduce -46.7% | 1.56% | −1.94 |
| BIIB Biogen Inc. | Reduce -20.1% | 2.07% | −1.74 |
| ALNY Alnylam Pharmaceuticals Inc. | Sold out | 0.00% | −1.38 |
| THC Tenet Healthcare Corp. | Reduce -50.1% | 1.33% | −1.30 |
| UHS Universal Health Services-B | Reduce -49.6% | 1.22% | −1.19 |
| AGIO Agios Pharmaceuticals Inc. | Reduce -44.3% | 0.92% | −1.05 |
| ALKS Alkermes PLC | Reduce -48.5% | 0.85% | −0.90 |
| VTRS Viatris Inc. | Sold out | 0.00% | −0.41 |
Portfolio Buys Q2 2024 → Q3 2024
| BDX Becton Dickinson and Co. | New | 5.65% | +5.65 |
| BMRN Biomarin Pharmaceutical Inc. | Add +200.5% | 4.06% | +2.11 |
| QGEN Qiagen NV | Add +167.3% | 3.08% | +1.80 |
| BNTX Biontech SE-ADR | New | 1.44% | +1.44 |
| MDT Medtronic PLC | Add +26.4% | 9.15% | +1.36 |
| BAX Baxter International Inc. | Add +48.1% | 4.44% | +1.19 |
| HUM Humana Inc. | New | 1.15% | +1.15 |
| BMY Bristol-Myers Squibb Co. | Add +12.5% | 9.45% | +1.15 |
| CNC Centene Corp. | Add +111.1% | 2.17% | +1.06 |
| CVS CVS Health Corp. | Add +37.3% | 5.76% | +0.91 |
| INCY Incyte Corp. | Add +27.4% | 5.19% | +0.59 |
| BRKR Bruker Corp. | Add +37.7% | 3.33% | +0.58 |
| LEGN Legend Biotech Corp.-ADR | New | 0.57% | +0.57 |
| ZBH Zimmer Biomet Holdings Inc. | Add +24.7% | 3.47% | +0.03 |
| GEHC GE Healthcare Technology | Add +2.6% | 3.04% | +0.01 |
| CAH Cardinal Health Inc. | Add +9.3% | 3.93% | −0.01 |
| EW Edwards Lifesciences Corp. | Add +53.5% | 2.13% | −0.26 |
| IONS Ionis Pharmaceuticals Inc. | Add +24.0% | 2.56% | −0.46 |
| ELV Elevance Health Inc. | Add +8.2% | 4.15% | −0.77 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 40 | $461.0M | BMY, MRK, MDT, PFE, INCY |
| Q1 2026 | 42 | $423.5M | BMY, MRK, PFE, MDT, INCY |
| Q4 2025 | 36 | $438.7M | BMY, MRK, MDT, BDX, GILD |
| Q3 2025 | 41 | $403.3M | PFE, MDT, MRK, BMY, BDX |
| Q2 2025 | 38 | $305.9M | PFE, MDT, BMY, BDX, MRK |
| Q1 2025 | 33 | $312.2M | BMY, PFE, BDX, MDT, AMGN |
| Q4 2024 | 30 | $290.9M | PFE, MDT, BMY, GILD, BDX |
| Q3 2024 | 29 | $329.6M | BMY, MDT, GILD, PFE, CVS |
| Q2 2024 | 28 | $267.7M | GILD, PFE, BMY, MDT, ELV |
| Q1 2024 | 28 | $354.8M | MDT, PFE, BMY, CVS, CAH |